- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00110279
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)
Phase I Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study A)
Avian influenza (AI), or bird flu, has recently become a major health concern in Asia and other parts of the world. The purpose of this study is to test the safety of and immune response to a new AI vaccine in healthy adults.
Study hypothesis: Influenza A viruses are widely distributed in nature and infect a wide variety of birds and mammals. The direct transmission of avian influenza viruses from birds to humans has recently become a major health concern in Asia and other parts of the world, raising concern of a possible influenza pandemic in humans. This vaccine will evaluate the safety, infectivity and immunogenicity of Live Influenza A vaccine H9N2 (6-2) AA ca reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a cold-adapted, live attenuated virus vaccine administered intranasally for the protection of humans against pandemic influenza viruses of the H9N2 subtype.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
AI viruses in their natural reservoir in waterfowl are the source from which novel HA and NA subtypes are introduced into the human population, and have the potential to initiate an influenza pandemic. This study will evaluate the safety and immunogenicity of a live, attenuated, cold-adapted reassortant AI virus vaccine, H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca).
Patient participation in this study will be for at least 60 days, with patients followed for at least 42 days after vaccination. In this study, participants will be enrolled sequentially, from highest to lowest dose of vaccine, into one of three groups. At study entry at Day 0, participants will be admitted to the hospital in order to familiarize them with trial procedures. Blood and nasal wash samples will be collected prior to vaccination. On Day 2, participants will have a physical exam and will receive one dose of vaccine; the vaccine will be administered as nose drops. Participants will undergo directed physical examinations daily while they are in the hospital. Nasal washes will also be collected daily from the day of admission through the day prior to discharge to test for the presence of vaccine virus. Participants may be discharged from the hospital after 3 consecutive negative viral cultures, but not before Day 14. Additional blood collection will occur daily from Day 0 to Day 7 and again on Day 21. Participants will return for follow-up visits 28 to 32 days and 42 to 46 days after receiving the vaccine. Blood and nasal wash collection will occur at these 2 study visits, and participants will also have directed physical exams.
Depending on the immune response to the first dose of vaccine, some participants may be asked to return to the hospital 1 to 2 months after their first vaccination to receive an additional dose of vaccine.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21205
- Johns Hopkins School of Public Health
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Born after 1968
- Good general health
- Available for the duration of the trial
Exclusion Criteria:
- Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease
- Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study
- Liver, renal, or hematologic disease
- Alcohol or drug abuse within 12 months of study entry
- History of severe allergic reaction or anaphylaxis
- Current asthma or reactive airway disease
- History of Guillain-Barre syndrome
- HIV-1 infected
- Hepatitis C virus infected
- Positive for hepatitis B surface antigen (HBsAg)
- Known immunodeficiency syndrome
- Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical corticosteroids are not excluded.
- Live vaccine within 4 weeks of study entry
- Killed vaccine within 2 weeks of study entry
- Absence of spleen
- Blood products within 6 months of study entry
- Current smoker
- Have traveled to the Southern Hemisphere or Asia within 30 days prior to study entry
- Have traveled on a cruise ship within 30 days prior to study entry
- Work in the poultry industry
- Investigational agents within 60 days prior to study entry, or currently participating in another investigational vaccine or drug trial
- Allergy to eggs or egg products
- Purified protein derivative (PPD) positive (positive tuberculosis [TB] test)
- Family member with immunodeficiency
- Other condition that, in the opinion of the investigator, would affect the participant's participation in the study
- Pregnant or breastfeeding
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 1
One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops.
|
Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
|
Experimenteel: 2
One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops.
This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.
|
Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Frequency of vaccine-related reactogenicity events and other adverse effects for each dose of the H9N2 G9/AA ca reassortant vaccine
Tijdsspanne: Throughout study
|
Throughout study
|
Immunogenicity and infectivity for each dose of the H9N2 G9/AA ca reassortant vaccine
Tijdsspanne: Throughout study
|
Throughout study
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
To compare antibody responses
Tijdsspanne: At Days 28 and 42
|
At Days 28 and 42
|
To determine the number of vaccinees infected with the H9N2 G9/AA ca reassortant vaccine candidate.
Tijdsspanne: Throughout study
|
Throughout study
|
If 10^7 , 10^5 , and 10^3 TCID50 doses of vaccine are administered, to compare the infectivity rates, safety, and immunogenicity between dose groups, and to estimate the HID50 for this vaccine
Tijdsspanne: Throughout study
|
Throughout study
|
Om de fenotypische stabiliteit van de verspreiding van het vaccinvirus te bepalen
Tijdsspanne: Gedurende de hele studie
|
Gedurende de hele studie
|
To determine whether immunogenicity is enhanced by a second dose of vaccine, and whether the first dose of vaccine restricts replication of the second dose
Tijdsspanne: At study completion
|
At study completion
|
Evalueren van door T-cellen gemedieerde en aangeboren immuunresponsen tegen de H9N2 G9/AA ca reassorterende vaccinkandidaat
Tijdsspanne: Gedurende de hele studie
|
Gedurende de hele studie
|
Het ontwikkelen van een serumbank zodat het vermogen van de H9N2 G9/AA ca reassortant-vaccinkandidaat om HI en neutraliserende antilichamen tegen toekomstige H9N2-griepvirussen op te wekken kan worden getest
Tijdsspanne: Gedurende de hele studie
|
Gedurende de hele studie
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Ruth A. Karron, MD, Center of Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health
Publicaties en nuttige links
Algemene publicaties
- Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR, Subbarao K. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine. 2003 Oct 1;21(27-30):4430-6. doi: 10.1016/s0264-410x(03)00430-4.
- Choi YK, Ozaki H, Webby RJ, Webster RG, Peiris JS, Poon L, Butt C, Leung YH, Guan Y. Continuing evolution of H9N2 influenza viruses in Southeastern China. J Virol. 2004 Aug;78(16):8609-14. doi: 10.1128/JVI.78.16.8609-8614.2004.
- Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis. 2004 Aug;4(8):499-509. doi: 10.1016/S1473-3099(04)01105-3.
- Swayne DE. Vaccines for List A poultry diseases: emphasis on avian influenza. Dev Biol (Basel). 2003;114:201-12.
- Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis. 2009 Mar 1;199(5):711-6. doi: 10.1086/596558.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CIR 211 (Study A)
- H.22.05.03.11.B2
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Virusziekten
-
U.S. Army Medical Research and Development CommandVoltooid
-
ModernaTX, Inc.Actief, niet wervend
-
ModernaTX, Inc.WervingRespiratoir sincytieel virusCanada, Verenigd Koninkrijk, Japan, Verenigde Staten, Chili, Denemarken, Panama, Zuid-Afrika
-
Merck Sharp & Dohme LLCVoltooidRespiratoir sincytieel virusVerenigd Koninkrijk
-
Dalhousie UniversityImmunoVaccine Technologies, Inc. (IMV Inc.)VoltooidRespiratoir sincytieel virusCanada
-
ModernaTX, Inc.WervingRespiratoir sincytieel virusCanada, Verenigde Staten, Verenigd Koninkrijk, Puerto Rico
-
ModernaTX, Inc.Actief, niet wervendRespiratoir sincytieel virusVerenigde Staten, Panama
-
ModernaTX, Inc.Actief, niet wervendRespiratoir sincytieel virusVerenigde Staten, Spanje, Taiwan, Korea, republiek van, Singapore, Canada, België, Finland, Japan, Verenigd Koninkrijk, Chili, Nieuw-Zeeland, Zuid-Afrika, Australië, Puerto Rico, Argentinië, Costa Rica, Polen, Bangladesh, Colombia en meer
-
Leiden University Medical CenterUMC Utrecht; Erasmus Medical Center; Leiden University; Netherlands Institute of...Voltooid
-
Meissa Vaccines, Inc.WervingRespiratoir syncytieel virus (RSV)Verenigde Staten
Klinische onderzoeken op H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthVoltooidVirusziekten | InfluenzaVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthVoltooidVirusziekten | InfluenzaVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...VoltooidVirusziekten | InfluenzaVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...VoltooidInfluenza A-virus, subtype H7N9Verenigde Staten